Grant: Doctoral Research Award: Canada Graduate Scholarships
McGill University
$105,000.00
Combining nelfinavir and carboplatin to induce immunogenic cell death in high grade serous ovarian cancer
FY 2023-24
Summary
High grade serous ovarian cancer (HGSOC) is the deadliest gynecological cancer, and the 8th leading cause of cancer-related deaths among women world-wide. Typically, HGSOC is treated with surgery and chemotherapy with carboplatin (CP). Initial treatment is often successful, but the cancer often returns, becoming CP-resistant. Therefore, new therapies are desperately needed for CP-resistant ovarian cancer patients. A potential drug that could be used with CP to kill HGSOC cells is nelfinavir (NFV). Past studies have shown the ability of NFV to kill HGSOC cells, regardless of their sensitivity to CP. More importantly, NFV may be capable of inducing a process known as immunogenic cell death (ICD). ICD is a type of cell death that involves the stimulation of the immune system. By inducing ICD in HGSOC, NFV may activate immune cells to target and kill the cancer, and act as a "vaccine" to prevent recurrence of HGSOC after initial remission. CP on its own cannot induce ICD, as it kills cancer cells without immune system activation. NFV has been shown to activate some of the necessary cellular pathways required for ICD that CP cannot activate alone. Therefore, the goal of this project will be to determine if NFV, when added to standard CP treatment, is capable of triggering ICD in HGSOC cells. NFV is already approved for treating other conditions and could easily be repurposed for use against HGSOC, providing a desperately needed treatment option for HGSOC patients.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
497040
Name
Forgie Benjamin
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Combining nelfinavir and carboplatin to induce immunogenic cell death in high grade serous ovarian cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Chemotherapy; Drug Repurposing; Immunogenic Cell Death; Immunology; Integrated Stress Response; Ovarian Cancer
Abstract
High grade serous ovarian cancer (HGSOC) is the deadliest gynecological cancer, and the 8th leading cause of cancer-related deaths among women world-wide. Typically, HGSOC is treated with surgery and chemotherapy with carboplatin (CP). Initial treatment is often successful, but the cancer often returns, becoming CP-resistant. Therefore, new therapies are desperately needed for CP-resistant ovarian cancer patients. A potential drug that could be used with CP to kill HGSOC cells is nelfinavir (NFV). Past studies have shown the ability of NFV to kill HGSOC cells, regardless of their sensitivity to CP. More importantly, NFV may be capable of inducing a process known as immunogenic cell death (ICD). ICD is a type of cell death that involves the stimulation of the immune system. By inducing ICD in HGSOC, NFV may activate immune cells to target and kill the cancer, and act as a "vaccine" to prevent recurrence of HGSOC after initial remission. CP on its own cannot induce ICD, as it kills cancer cells without immune system activation. NFV has been shown to activate some of the necessary cellular pathways required for ICD that CP cannot activate alone. Therefore, the goal of this project will be to determine if NFV, when added to standard CP treatment, is capable of triggering ICD in HGSOC cells. NFV is already approved for treating other conditions and could easily be repurposed for use against HGSOC, providing a desperately needed treatment option for HGSOC patients.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Forgie, Benjamin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~